Trending

gastroenterology

AZ takes control of Ironwood’s IBS drug in China

AZ takes control of Ironwood’s IBS drug in China

AstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an

X

AZ takes control of Ironwood’s IBS drug in China

https://pharmaphorum.com/news/az-takes-control-of-ironwoods-ibs-drug-in-china/

J&J gets Stelara okay in Europe for ulcerative colitis

J&J gets Stelara okay in Europe for ulcerative colitis

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new

X

J&J gets Stelara okay in Europe for ulcerative colitis

https://pharmaphorum.com/news/jj-gets-stelara-okay-in-europe-for-ulcerative-colitis/

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab,

X

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

https://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/

EU regulators slap safety restriction on Pfizer’s Xeljanz

EU regulators slap safety restriction on Pfizer’s Xeljanz

European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher

X

EU regulators slap safety restriction on Pfizer’s Xeljanz

https://pharmaphorum.com/news/eu-regulators-slap-safety-restriction-on-pfizers-xeljanz/

J&J unveils top pipeline prospects, with main focus on cancer

J&J unveils top pipeline prospects, with main focus on cancer

Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans

X

J&J unveils top pipeline prospects, with main focus on cancer

https://pharmaphorum.com/news/jj-unveils-top-pipeline-prospects-cancer/

Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial

Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard –

X

Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial

https://pharmaphorum.com/news/takedas-entyvio-outperforms-abbvies-humira-in-gi-trial/

Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow

Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow

Ireland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be

X

Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow

https://pharmaphorum.com/news/cosmos-diarrhoea-drug-approved-threatening-salix-cash-cow/

Blueprint eyes quick filing for GIST drug avapritinib

Blueprint eyes quick filing for GIST drug avapritinib

Blueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set

X

Blueprint eyes quick filing for GIST drug avapritinib

https://pharmaphorum.com/news/blueprint-eyes-quick-filing-for-gist-drug-avapritinib/

Takeda to buy stem cell specialists TiGenix for $626m

Takeda to buy stem cell specialists TiGenix for $626m

Decision follows EU regulators’ decision to back Crohn’s stem cell therapy

X

Takeda to buy stem cell specialists TiGenix for $626m

https://pharmaphorum.com/news/takeda-buy-gastro-biotech-tigenix-463m/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com